Anaplastic large cell lymphoma T- and null-cell types – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:01:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anaplastic large cell lymphoma T- and null-cell types – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy https://clinicaltrials.eu/trial/study-of-dapagliflozin-to-prevent-heart-complications-during-lymphoma-treatment-in-patients-receiving-first-line-therapy/ Wed, 29 Apr 2026 15:06:52 +0000 https://clinicaltrials.eu/trial/study-of-dapagliflozin-to-prevent-heart-complications-during-lymphoma-treatment-in-patients-receiving-first-line-therapy/ This study focuses on patients with different types of lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and T-cell lymphomas. The research examines whether a medication called dapagliflozin can protect the heart from potential damage during standard cancer treatment. Dapagliflozin belongs to a group of medications known as SGLT2 inhibitors, which are typically used to treat diabetes.

The study will test if taking dapagliflozin while receiving standard lymphoma treatment can help prevent heart-related side effects. Participants will receive either dapagliflozin or placebo tablets for 6 months while undergoing their regular cancer treatment. The medication or placebo will be taken by mouth once daily.

During the study, doctors will monitor heart function using various tests to measure how well the heart is working. These tests include examining heart muscle movement, blood flow patterns, and checking certain substances in the blood that can indicate heart health. The study will also track any heart-related symptoms that participants may experience during their treatment.

]]> Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment https://clinicaltrials.eu/trial/study-of-lorlatinib-for-patients-with-alk-anaplastic-large-cell-lymphoma-after-ineffective-alk-inhibitor-treatment/ Wed, 29 Apr 2026 15:03:26 +0000 https://clinicaltrials.eu/trial/study-of-lorlatinib-for-patients-with-alk-anaplastic-large-cell-lymphoma-after-ineffective-alk-inhibitor-treatment/ This clinical trial is focused on studying a type of cancer known as Anaplastic Large Cell Lymphoma (ALCL) that expresses a protein called ALK. This study is specifically for patients whose lymphoma has returned or has not responded to previous treatments with medications known as ALK inhibitors. The treatment being tested in this trial is a drug called lorlatinib, which is also known by its code name PF-06463922. Lorlatinib is taken orally in the form of film-coated tablets.

The purpose of the study is to understand how well lorlatinib works in patients with ALK-positive lymphoma who have not had success with other ALK inhibitor treatments. Participants in the study will take lorlatinib tablets and will be monitored over a period of time to see how their lymphoma responds to the treatment. The study will also look at other aspects such as the progression of the disease, overall survival, any side effects experienced, and the quality of life of the participants.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information on the effectiveness of lorlatinib for patients with this specific type of lymphoma, potentially offering a new treatment option for those who have not benefited from existing therapies.

]]> Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma https://clinicaltrials.eu/trial/study-of-nivolumab-for-children-and-adults-with-relapsed-or-refractory-alk-anaplastic-large-cell-lymphoma/ Wed, 29 Apr 2026 14:59:04 +0000 https://clinicaltrials.eu/trial/study-of-nivolumab-for-children-and-adults-with-relapsed-or-refractory-alk-anaplastic-large-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called anaplastic large cell lymphoma (ALCL), which is a rare form of non-Hodgkin lymphoma. Specifically, the trial is looking at cases where the cancer has returned or not responded to previous treatments, known as relapsing/refractory ALK+ anaplastic large cell lymphoma. The treatment being tested in this study is a medication called nivolumab, which is also known by its code name BMS936558. Nivolumab is a type of immunotherapy, which means it helps the body’s immune system fight cancer.

The purpose of this study is to evaluate how effective nivolumab is in treating patients with this type of lymphoma. The study is divided into two groups, or cohorts. In the first group, patients with active disease will receive nivolumab to see how well it can reduce or eliminate the cancer. In the second group, patients who are in complete remission after a relapse will receive nivolumab as a way to help keep the cancer from coming back. The study will monitor patients over a period of time to assess their response to the treatment and to track their health and any side effects they may experience.

Participants in the study will receive nivolumab through an intravenous infusion, which means the medication is given directly into a vein. The study will follow patients for several years to gather information on the long-term effects and benefits of the treatment. This research aims to provide valuable insights into the potential of nivolumab as a treatment option for patients with relapsing or refractory ALK+ anaplastic large cell lymphoma.

]]> Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors https://clinicaltrials.eu/trial/study-of-brigatinib-for-children-and-young-adults-with-alk-anaplastic-large-cell-lymphoma-inflammatory-myofibroblastic-tumors-or-other-solid-tumors/ Wed, 29 Apr 2026 14:58:26 +0000 https://clinicaltrials.eu/trial/study-of-brigatinib-for-children-and-young-adults-with-alk-anaplastic-large-cell-lymphoma-inflammatory-myofibroblastic-tumors-or-other-solid-tumors/ This clinical trial is focused on studying the effects of a medication called Brigatinib in children and young adults who have certain types of cancer. The cancers being studied include Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), and other solid tumors. Brigatinib is taken in the form of film-coated tablets and is being tested to see how well it works in treating these cancers.

The purpose of the study is to find the best dose of Brigatinib for young patients and to understand how the body processes the medication. The study will also look at how effective Brigatinib is in shrinking tumors and improving the health of patients with these specific types of cancer. Participants in the study will take the medication and be monitored by healthcare professionals over a period of time to observe any changes in their condition.

During the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Brigatinib. The study aims to gather important information that could help improve treatment options for young patients with these cancers in the future. The trial is expected to continue until 2030, allowing researchers to collect comprehensive data on the medication’s safety and effectiveness.

]]> Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma https://clinicaltrials.eu/trial/study-of-crizotinib-and-temsirolimus-for-children-with-alk-ros1-or-met-positive-cancers-including-neuroblastoma-and-rhabdomyosarcoma/ Wed, 29 Apr 2026 14:56:42 +0000 https://clinicaltrials.eu/trial/study-of-crizotinib-and-temsirolimus-for-children-with-alk-ros1-or-met-positive-cancers-including-neuroblastoma-and-rhabdomyosarcoma/ This clinical trial is focused on studying certain types of cancer in children, specifically those that are positive for ALK, ROS1, or MET genes. The cancers being studied include Neuroblastoma, Rhabdomyosarcoma, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, and other related malignancies. The treatment being tested is a medication called Crizotinib, which may be used alone or in combination with another drug called Temsirolimus. Crizotinib is also known by its code name PF-02341066 and is available in different forms, such as capsules and oral solutions.

The purpose of this study is to find the best dose of Crizotinib when used with Temsirolimus and to assess the safety and initial effectiveness of Crizotinib on its own in treating these specific gene-positive tumors. Participants in the study will receive either Crizotinib alone or in combination with Temsirolimus, depending on their specific cancer type and genetic markers. The study will monitor how the body responds to the treatment and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and tests to track their progress and the impact of the treatment on their cancer. The study aims to gather important information that could help improve treatment options for children with these types of cancers in the future. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study is expected to continue until the end of 2029.

]]> Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma https://clinicaltrials.eu/trial/study-on-vinblastine-for-children-and-adolescents-with-standard-risk-alk-positive-anaplastic-large-cell-lymphoma/ Wed, 29 Apr 2026 14:24:47 +0000 https://clinicaltrials.eu/trial/study-on-vinblastine-for-children-and-adolescents-with-standard-risk-alk-positive-anaplastic-large-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called anaplastic large cell lymphoma (ALCL), which is a rare form of non-Hodgkin lymphoma. Specifically, the study is looking at cases that are ALK-positive, meaning they have a particular genetic feature that can affect how the cancer grows. The trial is aimed at children and adolescents who have been newly diagnosed with this condition and are considered to have a standard risk level.

The treatment being tested in this study is a medication called Vinblastine Sulfate. This medication is given as an injection into a vein and is known to be a type of drug that interferes with the growth of cancer cells. The purpose of the study is to see if using Vinblastine Sulfate alone for a period of 24 months can effectively treat at least 75% of patients with this type of lymphoma.

Participants in the study will receive Vinblastine Sulfate and will be monitored over time to see how well the treatment works. The study will track the health of participants for at least three years to understand the long-term effects of the treatment. The goal is to determine the likelihood of patients remaining free from cancer-related events, such as the cancer returning or worsening, over a three-year period. This information will help doctors understand if Vinblastine Sulfate is a good treatment option for this type of cancer in young patients.

]]> Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation https://clinicaltrials.eu/trial/study-of-romidepsin-and-drug-combination-for-young-patients-with-peripheral-t-cell-lymphomas-before-stem-cell-transplantation/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-of-romidepsin-and-drug-combination-for-young-patients-with-peripheral-t-cell-lymphomas-before-stem-cell-transplantation/ This clinical trial is focused on studying certain types of lymphoma, which is a cancer of the lymphatic system. The specific types being studied are Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, and Peripheral T-cell Lymphoma, NOS. The treatment being tested is a combination of a drug called Romidepsin and a chemotherapy regimen known as CHOEP. Romidepsin is a type of medication that is given as a solution for injection and works by inhibiting certain enzymes in cancer cells, which may help to stop their growth.

The purpose of this study is to evaluate the safety and effectiveness of this treatment combination as a first-line therapy before a procedure called hematopoietic stem cell transplantation, which is a type of treatment that replaces damaged or destroyed bone marrow with healthy bone marrow stem cells. The study is divided into two phases. In the first phase, the focus is on determining the safest dose of the treatment combination. In the second phase, the study aims to assess how well the treatment works in terms of preventing the cancer from getting worse or coming back.

Participants in the study will receive the treatment combination and will be monitored over time to see how their cancer responds to the treatment. The study will also look at the overall response rate, which measures how many patients experience a reduction in cancer size or symptoms, and the overall survival rate, which tracks how long patients live after starting the treatment. The study is expected to continue until March 2025, with ongoing assessments to ensure the safety and effectiveness of the treatment.

]]>